Ann Clin Microbiol Antimicrob 2009, 24:27.CrossRef 6. McIsaac WJ, Mazzulli T, Permaul J, Moineddin R, BAY 80-6946 price Low DE: Community-acquired antibiotic resistance in urinary isolates from adult women in Canada. Can J Infect Dis Med Microbiol 2006, 17:337–340.PubMed 7. Muratani T, Matsumoto T: Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. Int J Antimicrob Agents 2006,28(suppl 1):10–13.CrossRef 8. Arslan H, Azap OK, Ergonul O, Timurkaynak F, Urinary Tract Infection Study Group: Risk factors for ciprofloxacin resistance among see more Escherichia coli strains isolated
from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005, 56:914–918.PubMedCrossRef 9. Tolun V, Kucukbasmaci O, Torumkuney-Akbulut D, Catal C, Anğ-Küçüker M, Anğ O: Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in Escherichia coli and Klebsiella pneumoniae strains. Clin Microbiol Infect 2004, 10:72–75.PubMedCrossRef 10. Lin CY, Huang SH, Chen TC, Lu PL, Lin WR, Chen YH: Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates. J Microbiol Immunol Infect 2008, 41:325–331.PubMed 11. Killgore KM, March KL, Guglielmo BJ: Risk factors for community-acquired ciprofloxacin resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004, 38:1148–1152.PubMedCrossRef
12. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J: Relationship between quinolones use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob
Agents Chemother 1995, PD98059 price 39:520–524.PubMed 13. Cebríán L, Rodríguez JC, Escribiano I, Royo SG: Evaluation of several fluoroquinolones and beta-lactams in terms of their capability to restrict the selection of fluoroquinolone-resistant Salmonella: in vitro models. APMIS 2007, 15:1376–1382.CrossRef 14. Kim MJ, Yun HJ, Kang JW, Kim S, Kwak JH, Choi EC: In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates. J Antimicrob Chemother 2003, 51:1011–1016.PubMedCrossRef 15. Browne FA, Clark C, Bozdogan B, Dewasse BE, Jacobs MR, Appelbaum PC: Single IMP dehydrogenase and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin. Int J Antimicrob Agents 2002, 20:93–99.PubMedCrossRef 16. Sierra JM, Cabeza JG, Ruiz Chaler M, Montero T, Hernandez J, Mensa J, Llagostera M, Vila J: The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae . Clin Microbiol Infect 2005, 11:750–758.PubMedCrossRef 17. Drago L, Nicola L, De Vecchi E: A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp .